Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [11C]Metoclopramide
Open Access
- 22 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Molecular Imaging & Biology
- Vol. 23 (2), 180-185
- https://doi.org/10.1007/s11307-021-01582-4
Abstract
Purpose To assess in healthy volunteers the whole-body distribution and dosimetry of [11C]metoclopramide, a new positron emission tomography (PET) tracer to measure P-glycoprotein activity at the blood-brain barrier. Procedures Ten healthy volunteers (five women, five men) were intravenously injected with 387 ± 49 MBq of [11C]metoclopramide after low dose CT scans and were then imaged by whole-body PET scans from head to upper thigh over approximately 70 min. Ten source organs (brain, thyroid gland, right lung, myocardium, liver, gall bladder, left kidney, red bone marrow, muscle and the contents of the urinary bladder) were manually delineated on whole-body images. Absorbed doses were calculated with QDOSE (ABX-CRO) using the integrated IDAC-Dose 2.1 module. Results The majority of the administered dose of [11C]metoclopramide was taken up into the liver followed by urinary excretion and, to a smaller extent, biliary excretion of radioactivity. The mean effective dose of [11C]metoclopramide was 1.69 ± 0.26 μSv/MBq for female subjects and 1.55 ± 0.07 μSv/MBq for male subjects. The two organs receiving the highest radiation doses were the urinary bladder (10.81 ± 0.23 μGy/MBq and 8.78 ± 0.89 μGy/MBq) and the liver (6.80 ± 0.78 μGy/MBq and 4.91 ± 0.74 μGy/MBq) for female and male subjects, respectively. Conclusions [11C]Metoclopramide showed predominantly renal excretion, and is safe and well tolerated in healthy adults. The effective dose of [11C]metoclopramide was comparable to other 11C-labeled PET tracers.Keywords
Funding Information
- Austrian Science Fund (KLI 694-B30)
- Austrian Research Promotion Agency (FEMtec)
This publication has 21 references indexed in Scilit:
- Imaging P-Glycoprotein Induction at the Blood–Brain Barrier of a β-Amyloidosis Mouse Model with 11C-Metoclopramide PETJournal of Nuclear Medicine, 2019
- Imaging P‐Glycoprotein Function at the Blood–Brain Barrier as a Determinant of the Variability in Response to Central Nervous System DrugsClinical Pharmacology & Therapeutics, 2019
- IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantomsEJNMMI Research, 2017
- Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood–Brain Barrier, Is Compromised in Patients with Mild Alzheimer DiseaseJournal of Nuclear Medicine, 2014
- Radiation dose estimates for carbon-11-labelled PET tracersNuclear Medicine and Biology, 2012
- Blood–brain barrier P-glycoprotein function in Alzheimer's diseaseBrain, 2011
- Identification of Novel Metoclopramide Metabolites in Humans: In Vitro and In Vivo StudiesDrug Metabolism and Disposition, 2010
- P-Glycoprotein Function at the Blood–Brain Barrier in Humans Can Be Quantified with the Substrate Radiotracer 11C-N-Desmethyl-LoperamideJournal of Nuclear Medicine, 2010
- Preface, Executive Summary and GlossaryAnnals of the ICRP, 2007
- Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomographyClinical Pharmacology & Therapeutics, 2005